HIVe Home
ID#: PAR-11-120     Posted: 15 Mar 2011
NIAID Research Demonstration and Dissemination Projects (R18) PAR-11-120
Deadline: 16 May 2013
Apply Here
Topics/Fields of Support: Adjuvants, Animal model studies, Clinical trial site challenges, Human genomics, Immune escape, Innate immunity, Mucosal immunity, Novel immunogens, inserts and vectors, Prevention strategies, Social, ethical, access and regulatory issues, T cell immunity, Vaccine concepts and design, Viral Diversity, Other
National Institute of Allergy and Infectious Diseases, NIH, HHS

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. NIAID is one of the 27 Institutes and Centers of the National Institutes of Health (NIH). NIH, like the Centers for Disease Control and Prevention (CDC), is part of the U. S. Department of Health and Human Services (HHS). NIH is the primary federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, please visit NIH (

Visit web site


Funding Opportunity Description

The mission of the National Institute of Allergy and Infectious Diseases (NIAID) is to conduct and support basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. To accomplish its mission, NIAID conducts and supports a comprehensive portfolio of research on the biology, pathogenesis, and host response to HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat the many infectious, immune-mediated, and allergic diseases that afflict people throughout the world.

The Division of Allergy, Immunology and Transplantation (DAIT) is responsible for national and international extramural research programs in basic immunology, and in the etiology, treatment, and prevention of immune-mediated diseases, including rejection of transplanted organs, tissues, and cells; autoimmune diseases; asthma and allergic diseases; and primary immunodeficiency diseases. Capitalizing on major advances in understanding the mechanisms underlying these diseases, DAIT supports preclinical and clinical development of new tolerogenic and immunomodulatory approaches for the treatment and prevention of many immune-mediated diseases, and is the lead NIH component for research on transplantation.


This Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), specifically, the Division of Allergy, Immunology and Transplantation (DAIT), invites investigator-initiated Demonstration and Dissemination Research Project (R18) applications that may foster the application of existing knowledge  for control of immune-mediated diseases addressed within the specific  mission of DAIT, as described above. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of DAIT

1. Research Objectives

The National Institute of Allergy and Infectious Diseases (NIAID) invites Research Demonstration and Dissemination Project (R18) applications from institutions/organizations that propose studies which will develop and test strategies to accelerate the adoption and integration of evidence into practice.  The purpose of this FOA is to support dissemination and implementation studies to (1) develop innovative approaches to translating efficacious and/or evidence-based approaches and effective prevention modalities for immune-based disorders in the clinic, community, and other real-world settings; (2) test the effectiveness, sustainability, determinants, and cost-effectiveness of these approaches in a variety of real-world settings; and (3) examine the effectiveness of interventions as they are disseminated and implemented in real-world settings to reduce risk factors for and enhance prevention and treatment of immune-based disorders relevant to the NIAID mission. The ultimate goal of this program is to determine feasible and effective strategies to translate research findings into practice, to identify determinants of implementation effectiveness at all levels, and to accelerate the adoption, integration, and sustainability of evidence into practice and medical decision-making. 

This funding mechanism does not support:

  • The transfer of specific technology, development of educational programs, or the implementation of specific innovations by themselves outside of a research study.
  • Direct service programs intended solely to provide preventive or therapeutic care for immune-based diseases.
  • Clinical testing of a new technology or a new drug for treatment and evidence development .

Areas of NIAID Research Interests

Research interests at the NIAID include, but are not limited, to the topics below. These examples are not listed in order of priority and investigators are encouraged to choose their own topics. Topics considered to be non-responsive are described in the preceding paragraph.

  • Studies testing implementation approaches for the promotion and maintenance of health and methods of rehabilitation for immune-based diseases such as asthma, atopic dermatitis, allergic rhinitis, arthritis, systemic lupus erythematosus (SLE), multiple sclerosis (MS), primary immunodeficiency diseases, type 1 diabetes and transplant rejection.
  • Studies to compare the effectiveness of innovative disease management tools, tools for assessment of patient-reported outcomes, and shared decision making strategies for managing the care of patients with immune-based disorders.
  • Studies testing implementation approaches using clinical guidelines for the prevention, treatment and management of immune-based diseases.
  • Investigations to improve understanding of the determinants of effectiveness at all levels (patient, provider, systems, infrastructure, and community approaches) can be synergistically optimized to improve the clinical delivery of efficacious treatments for immune-based diseases and optimal management of their risk factors.

See grant posting webpage on NIH website for application details.


Application due dates: May 16, 2011; May 16, 2012; May 16, 2013 , by 5:00 PM local time of applicant organization.

Eligible Applicants

Eligible Organizations

Higher Education Institutions:

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

  • Hispanic-serving Institutions
  • Historically Black Colleges and Universities (HBCUs)
  • Tribally Controlled Colleges and Universities (TCCUs)
  • Alaska Native and Native Hawaiian Serving Institutions

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)


  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)
  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession


  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations

Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Foreign (non-U.S.) components of U.S. Organizations are not allowed.

Required Registrations

Applicant organizations must complete the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. Applicants must have a valid Dun and Bradstreet Universal Numbering System (DUNS) number in order to begin each of the following registrations.

All Program Directors/Principal Investigators (PD/PIs) must also work with their institutional officials to register with the eRA Commons or ensure their existing eRA Commons account is affiliated with the eRA Commons account of the applicant organization.

All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process at least four (4) weeks prior to the application due date.

Eligible Individuals (Project Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Project Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF 424 (R&R) Application Guide.   

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility
Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed. Resubmission applications may be submitted, according to the NIH Policy on Resubmission Applications from the SF 424 (R&R) Application Guide.


Application Submission Contacts Customer Support (Questions regarding registration and submission, downloading or navigating forms)
Contact Center Phone: 800-518-4726, Email:

GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)
Telephone 301-435-0714, TTY 301-451-5936

eRA Commons Help Desk(Questions regarding eRA Commons registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
TTY: 301-451-5939

Scientific/Research Contact(s)

Lawrence J. Prograis, Jr., M.D.
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases (NIAID)
Room 6207, MSC-6601
6610 Rockledge Drive
Bethesda, Maryland 20892-6601
Tel: 301-496-1886, Fax: 301-402-0175

Peer Review Contact(s)

Paul Amstad, Ph.D.
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases (NIAID)
Room 3121, MSC-7616
6700B Rockledge Drive
Bethesda, MD  20892-7616
FEDEX Zip:  20817-7616
Tel:  301-402-7098, Fax: 301-480-2408

Financial/Grants Management Contact(s)

Victoria P. Connors
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases (NIAID)
Room 2122, MSC-7614
6700B Rockledge Drive
Bethesda, MD  20892-7614
FEDEX Zip:  20817-7614
Tel:  301-402-5065, Fax: 301-493-0597